We are live on
!
Find out more
AG
Artal Group Portfolio holdings
AUM
$1.01B
1-Year Est. Return
29.84%
This Fund
S&P 500
This Quarter
Est. Return
-10.62%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.76B
AUM Growth
-$25.9M
(-0.93%)
Cap. Flow
+$293M
Cap. Flow
% of AUM
10.61%
Top 10 Holdings %
Top 10 Hldgs %
58.38%
Holding
114
New
31
Increased
18
Reduced
24
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Citigroup
C
|
+$14.9M |
| 2 |
Dollar General
DG
|
+$14.5M |
| 3 |
MJN
Mead Johnson Nutrition Company
MJN
|
+$12.2M |
| 4 |
Aptiv
APTV
|
+$9.58M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$9.21M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ACOR
Acorda Therapeutics
ACOR
|
+$11.8M |
| 2 |
Goldman Sachs
GS
|
+$8.41M |
| 3 |
Crown Castle
CCI
|
+$7.34M |
| 4 |
XOMA
Xoma
XOMA
|
+$7.26M |
| 5 |
FURX
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
|
+$5.55M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 22.6% |
| 2 | Healthcare | 22.12% |
| 3 | Consumer Staples | 1.28% |
| 4 | Financials | 0.7% |
| 5 | Real Estate | 0.24% |
Similar funds
BCM
GA
EPAM
WA
CT
AH
PIM
MAM
Artal Group's Q1 2014 Portfolio in Review
As of Q1 2014, Artal Group held 114 positions worth $2.76B, down 0.93% from $2.79B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Artal Group deployed $293M of net new capital in Q1 2014, opening 31 new positions and adding to 18 existing holdings. Its largest new stake was Citigroup: 300,000 shares worth $14.3M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 23% of assets, down from 35% a quarter earlier, followed by Healthcare and Consumer Staples.
On the sell side, the largest reduction was Acorda Therapeutics, an estimated $11.8M trimmed.
- Artal Group's largest Q1 2014 buy was Citigroup: 300,000 shares worth $14.3M.
- Artal Group added most to BioMarin Pharmaceuticals in Q1 2014, an estimated $9.21M increase.
- Artal Group's biggest Q1 2014 reduction was Acorda Therapeutics, cutting an estimated $11.8M.
- Artal Group fully exited Goldman Sachs in Q1 2014, selling an estimated $8.41M.
- Artal Group's ten largest holdings make up 58% of its $2.76B portfolio in Q1 2014.
- Artal Group opened 31 new positions and closed 20 in Q1 2014.
- Artal Group's portfolio value fell 0.93% quarter-over-quarter to $2.76B.
Based on Artal Group's 13F filing for Q1 2014, filed 15 May 2014.